Experienced life sciences logistics company, Biocair, has partnered with TrakCel and integrated their systems with OCELLOS to improve customer service, automation and visibility in the cell and gene therapy supply chain.

OCELLOS by TrakCel is an integrated cell orchestration solution designed to manage and streamline the cell, gene and immunotherapy supply chain. The platform ensures tracking of both chain of identity and chain of custody, both vital parts of the patient journey, to support the scalability of cell and gene therapy development.

Biocair has been delivering excellence in pharmaceutical, biotech and life science logistics for over 35 years. Most recently, the business has continued its investment in cell and gene therapy logistics by introducing a global team of dedicated specialists to deliver 24-hour global support, as well as collaborating with manufacturers on the design, production, supply and validation of temperature-controlled packaging systems.

Cell and gene therapy offers patients complete personalization of medicine – a revolutionary way to fight disease. These time-sensitive and life-changing medicines need innovative and flexible logistics solutions to ensure a safe, temperature-controlled and efficient delivery.

Integration with TrakCel’s orchestration platform is essential to ensure a chain of custody whereby all stakeholders have complete visibility of orders in transit. Chris Came, VP of Global Alliances & Client Services at TrakCel, says “We are so pleased to have such an experienced life sciences logistics specialist on board. By using OCELLOS, Biocair will become completely integrated in the cell and gene therapy supply chain and able to offer patients the best possible service.”

Came continues “OCELLOS accumulates and automates all the ‘moving parts’ in the cell and gene therapy supply chain. The platform allows visibility and control of onboarding, scheduling, management of timeslots and liaison with couriers. The integration will allow Biocair to further scale their cell and gene therapy logistics, whilst still being customer focussed and offering high levels of service.”

The system integration is a two-way relationship. OCELLOS will ‘speak’ to Biocair to ask for updates and distribute them accordingly to those who need them, whilst Biocair will also receive orders directly from the system.

Chris Good, Director of Cell & Gene Therapy Logistics at Biocair, comments “Biocair has always been customer focused, but this is even more important in the cell and gene sector. We want to give our customers full visibility and integration within the complex cell and gene therapy supply chain, which is why partnering with TrakCel is essential to providing health care professionals and patients peace of mind that their life-changing medicines will reach them in a timely and safe manner.”

ENDS

About Biocair
Since 1986, Biocair has established a global reputation as a leading GDP logistics specialist within the pharmaceutical, biotechnology and life sciences sectors. Biocair has built up a unique, client-centric approach by employing scientists in front-line logistics positions and assembling a team of best-in-class industry experts in quality, cold chain and regulatory compliance. Biocair focuses on providing the most comprehensive time-sensitive and temperature-controlled logistics services available whilst delivering flexible, tailored, cost-effective solutions to all its clients. It is committed to delivering complete end-to-end logistics solutions through its 24/7 operation and global network spanning across Europe, Africa, Asia and the Americas.

Biocair employs over 600 people worldwide and provides specialist logistics services to more than 160 countries through a global network of partners. Biocair’s offices are located in the UK, France, Belgium, Germany, USA, South Africa, China, Singapore and India.

In 2012 Biocair was acquired as an autonomous division by Geopost. Geopost is the largest parcel delivery network in Europe, which posted sales of €15.6 billion in 2022. Geopost is a holding company owned by Groupe La Poste.

For further information on Biocair, please visit www.biocair.com.

For more information please contact:
Allison Averitt
Content Marketing and Communications Specialist
Allison.Averitt@biocair.com

Katie Ford
PR & Content Account Director
Katie.ford@anicca.co.uk

About TrakCel
TrakCel is the market leading developer of integrated cell orchestration solutions. TrakCel has specifically designed these solutions to manage the international autologous and allogeneic cell, gene and immunotherapy value and supply chains. Its platform has evolved in collaboration with, and is increasingly adopted by, leading companies in the cell, gene and immunotherapy industries. TrakCel’s solutions enable real-time control for all organizations working across the entire therapeutic value chain. This control includes patient eligibility (commercial) and enrolment, sample collection, manufacturing and treatment delivery. The TrakCel platform accelerates global scale-up and scale-out of cell and gene therapy products, increasing efficiency and decreasing complexity, while safe-guarding Chain of Custody and Chain of Identity with a full electronic audit trail for administration compliance and traceability. TrakCel was founded in 2012. It's headquartered in Cardiff, UK with US offices in California. https://trakcel.com.

For more information:
IB Communications
Neil Hunter / Michelle Boxall
Tel: +44 (0) 20 8943 4685
trakcel@ibcomms.agency